Augustine Therapeutics Doses First Patient in CMT Clinical Trial of AGT-100216

Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease

Augustine Therapeutics has announced that the first patient has been dosed in their Phase I clinical trial of AGT-100216, a potential new treatment for Charcot-Marie-Tooth disease (CMT). This marks an exciting step forward in CMT research.

Read the full announcement here:
🔗 https://www.augustinetx.com/media/augustine-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-evaluating-lead-candidate-agt-100216-for-the-treatment-of-charcot-marie-tooth-disease